Savara

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. 

CEO
Matthew Pauls
CEOMatthew Pauls
Employees
70
Employees70
Headquarters
Langhorne, Pennsylvania
HeadquartersLanghorne, Pennsylvania
Founded
1995
Founded1995
Employees
70
Employees70

SVRA Key Statistics

Market cap
1.03B
Market cap1.03B
Price-Earnings ratio
-8.99
Price-Earnings ratio-8.99
Dividend yield
Dividend yield
Average volume
1.30M
Average volume1.30M
High today
$5.19
High today$5.19
Low today
$4.99
Low today$4.99
Open price
$5.07
Open price$5.07
Volume
668.10K
Volume668.10K
52 Week high
$7.01
52 Week high$7.01
52 Week low
$1.89
52 Week low$1.89

Stock Snapshot

The current Savara(SVRA) stock price is $5.12, with a market capitalization of 1.03B. The stock trades at a price-to-earnings (P/E) ratio of -8.99.

On 2026-05-26, Savara(SVRA) stock moved within a range of $4.99 to $5.19. With shares now at $5.12, the stock is trading +2.6% above its intraday low and -1.3% below the session's peak.

Trading activity shows a volume of 668.1K, compared to an average daily volume of 1.3M.

Over the past 52 weeks, Savara(SVRA) stock has traded between a high of $7.01 and a low of $1.89.

Over the past 52 weeks, Savara(SVRA) stock has traded between a high of $7.01 and a low of $1.89.

SVRA News

Simply Wall St 7h
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara

Earlier in May, Savara Inc. reported new Phase 3 IMPALA-2 data at the ATS 2026 meeting showing that nebulized molgramostim improved exercise capacity and relate...

New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara
Simply Wall St 3d
A Look At Savara Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations

Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers...

A Look At Savara Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations
TipRanks 6d
Savara presents poster at ATS 2026 International Conference on IMPALA-2

Savara (SVRA) presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new bio...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.